Your browser doesn't support javascript.
loading
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Cousin, Sophie; Cantarel, Coralie; Guegan, Jean-Philippe; Mazard, Thibault; Gomez-Roca, Carlos; Metges, Jean-Philippe; Bellera, Carine; Adenis, Antoine; Korakis, Iphigenie; Poureau, Pierre-Guillaume; Bourcier, Kevin; Toulmonde, Maud; Kind, Michèle; Rey, Christophe; Auzanneau, Céline; Bessede, Alban; Soubeyran, Isabelle; Italiano, Antoine.
Affiliation
  • Cousin S; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Cantarel C; Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France.
  • Guegan JP; Explicyte, 229 Cours de L'Argonne, Bordeaux, France.
  • Mazard T; Department of Medical Oncology, Institut Regional Du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
  • Gomez-Roca C; Department of Medical Oncology, IUCT, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France.
  • Metges JP; Department of Medical Oncology, CHRU de Brest - Hôpital Morvan, 2 Avenue Foch, 29609, Brest, France.
  • Bellera C; Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France; Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000, Bordeaux, France.
  • Adenis A; Department of Medical Oncology, Institut Regional Du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
  • Korakis I; Department of Medical Oncology, IUCT, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France.
  • Poureau PG; Department of Medical Oncology, CHRU de Brest - Hôpital Morvan, 2 Avenue Foch, 29609, Brest, France.
  • Bourcier K; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Toulmonde M; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Kind M; Department of Radiology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Rey C; Explicyte, 229 Cours de L'Argonne, Bordeaux, France.
  • Auzanneau C; Department of Biopathology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Bessede A; Explicyte, 229 Cours de L'Argonne, Bordeaux, France.
  • Soubeyran I; Department of Biopathology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
  • Italiano A; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France; University of Bordeaux, Bordeaux, France; Gustave Roussy, Villejuif, France. Electronic address: a.italiano@bordeaux.unicancer.fr.
Eur J Cancer ; 162: 161-169, 2022 02.
Article in En | MEDLINE | ID: mdl-34998048
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biliary Tract Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Affiliation country: France Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biliary Tract Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Affiliation country: France Country of publication: United kingdom